NKG2D expression on HIV-specific CD8+ T cells is reduced in viremic HIV-1-infected patients but maintained in HIV controllers

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):17-20. doi: 10.1097/QAI.0b013e318274579f.

Abstract

NKG2D mediates an important costimulatory pathway in CD8 T cells. In HIV infection, the authors found that NKG2D expression on both total CD8 and HIV-specific CD8 T cells was significantly lower in viremic patients than in HIV controllers. Antiretroviral therapy partially restored NKG2D expression on HIV-specific CD8 T cells. The authors observed a negative correlation between the respective expression levels of CD38 and NKG2D on total CD8 and HIV-specific CD8 T cells. The maintenance of NKG2D expression on CD8 T cells in HIV controllers may contribute to better cell function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • CD8-Positive T-Lymphocytes / chemistry*
  • CD8-Positive T-Lymphocytes / immunology*
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Long-Term Survivors
  • HIV-1 / immunology*
  • Humans
  • NK Cell Lectin-Like Receptor Subfamily K / analysis*
  • Treatment Outcome
  • Viremia / immunology

Substances

  • Anti-HIV Agents
  • KLRK1 protein, human
  • NK Cell Lectin-Like Receptor Subfamily K